{"id":"https://openalex.org/W3011600802","doi":"https://doi.org/10.1016/j.msard.2019.11.068","title":"Long-Term Reduction of Relapse Rate and Confirmed Disability Progression After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis","display_name":"Long-Term Reduction of Relapse Rate and Confirmed Disability Progression After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis","publication_year":2020,"publication_date":"2020-01-01","ids":{"openalex":"https://openalex.org/W3011600802","doi":"https://doi.org/10.1016/j.msard.2019.11.068","mag":"3011600802"},"language":"en","primary_location":{"id":"doi:10.1016/j.msard.2019.11.068","doi":"https://doi.org/10.1016/j.msard.2019.11.068","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.msard.2019.11.068","pdf_url":null,"source":{"id":"https://openalex.org/S2764622253","display_name":"Multiple Sclerosis and Related Disorders","issn_l":"2211-0348","issn":["2211-0348","2211-0356"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis and Related Disorders","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5075965534","display_name":"Riadh Gouider","orcid":"https://orcid.org/0000-0001-9615-3797","observed_orcids":["https://orcid.org/0000-0001-9615-3797"]},"institutions":[{"id":"https://openalex.org/I4403386600","display_name":"Facult\u00e9 de m\u00e9decine de Tunis","ror":"https://ror.org/03pyhhg10","country_code":"TN","type":"education","lineage":["https://openalex.org/I4403386600","https://openalex.org/I63596082"]},{"id":"https://openalex.org/I63596082","display_name":"Tunis El Manar University","ror":"https://ror.org/029cgt552","country_code":"TN","type":"education","lineage":["https://openalex.org/I63596082"]}],"countries":["TN"],"is_corresponding":false,"raw_author_name":"Riadh Gouider","raw_affiliation_strings":["Department of Neurology, Universit\u00e9 de Tunis El Manar, Facult\u00e9 de M\u00e9decine de Tunis, Tunis, Tunisia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, Universit\u00e9 de Tunis El Manar, Facult\u00e9 de M\u00e9decine de Tunis, Tunis, Tunisia","institution_ids":["https://openalex.org/I4403386600","https://openalex.org/I63596082"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015754502","display_name":"Gavin Giovannoni","orcid":"https://orcid.org/0000-0001-9995-1700","observed_orcids":["https://orcid.org/0000-0001-9995-1700"]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gavin Giovannoni","raw_affiliation_strings":["Queen Mary University of London, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen Mary University of London, London, United Kingdom","institution_ids":["https://openalex.org/I166337079"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054874316","display_name":"Ludwig Kappos","orcid":"https://orcid.org/0000-0003-4175-5509","observed_orcids":["https://orcid.org/0000-0003-4175-5509"]},"institutions":[{"id":"https://openalex.org/I1850255","display_name":"University of Basel","ror":"https://ror.org/02s6k3f65","country_code":"CH","type":"education","lineage":["https://openalex.org/I1850255"]},{"id":"https://openalex.org/I2802542264","display_name":"University Hospital of Basel","ror":"https://ror.org/04k51q396","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I2802542264"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Ludwig Kappos","raw_affiliation_strings":["University Hospital Basel, University of Basel, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital Basel, University of Basel, Basel, Switzerland","institution_ids":["https://openalex.org/I1850255","https://openalex.org/I2802542264"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104805489","display_name":"Stephen L. Hauser","orcid":"https://orcid.org/0000-0002-4932-4001","observed_orcids":["https://orcid.org/0000-0002-4932-4001"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen L. Hauser","raw_affiliation_strings":["University of California, San Francisco, San Francisco, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of California, San Francisco, San Francisco, United States","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031171090","display_name":"Xavier Montalb\u00e1n","orcid":"https://orcid.org/0000-0002-0098-9918","observed_orcids":["https://orcid.org/0000-0002-0098-9918"]},"institutions":[{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Xavier Montalban","raw_affiliation_strings":["Division of Neurology, University of Toronto, Toronto, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Neurology, University of Toronto, Toronto, Canada","institution_ids":["https://openalex.org/I185261750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071219650","display_name":"Harold Koendgen","orcid":"https://orcid.org/0000-0002-8496-4952","observed_orcids":["https://orcid.org/0000-0002-8496-4952"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Harold Koendgen","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113891272","display_name":"Kalpesh Prajapati","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kalpesh Prajapati","raw_affiliation_strings":["GCE Solutions Inc, Amsterdam, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GCE Solutions Inc, Amsterdam, Netherlands","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104210008","display_name":"Marianna Manfrini","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Marianna Manfrini","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5076338840","display_name":"Jerry S. Wolinsky","orcid":"https://orcid.org/0000-0002-8197-2762","observed_orcids":["https://orcid.org/0000-0002-8197-2762"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I919571938","display_name":"The University of Texas Health Science Center at Houston","ror":"https://ror.org/03gds6c39","country_code":"US","type":"education","lineage":["https://openalex.org/I919571938"]}],"countries":["ES","US"],"is_corresponding":false,"raw_author_name":"Jerry S. Wolinsky","raw_affiliation_strings":["McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, United States","Vall d'Hebron University Hospital, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, United States","institution_ids":["https://openalex.org/I919571938"]},{"raw_affiliation_string":"Vall d'Hebron University Hospital, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3050,"currency":"USD","value_usd":3050},"apc_paid":null,"fwci":0.161,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.43684872,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"37","issue":null,"first_page":"101593","last_page":"101593"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ocrelizumab","display_name":"ocrelizumab","score":1.0},{"id":"https://openalex.org/keywords/relapsing-multiple-sclerosis","display_name":"relapsing multiple sclerosis","score":0.9959999918937683},{"id":"https://openalex.org/keywords/relapse-rate","display_name":"relapse rate","score":0.8679999709129333},{"id":"https://openalex.org/keywords/disability-progression","display_name":"disability progression","score":0.9890000224113464},{"id":"https://openalex.org/keywords/long-term-follow-up","display_name":"long-term follow-up","score":0.6650000214576721},{"id":"https://openalex.org/keywords/open-label-extension","display_name":"open-label extension","score":0.8820000290870667},{"id":"https://openalex.org/keywords/anti-cd20-therapy","display_name":"anti-CD20 therapy","score":0.796999990940094}],"concepts":[{"id":"https://openalex.org/C2778843634","wikidata":"https://www.wikidata.org/wiki/Q2013780","display_name":"Ocrelizumab","level":4,"score":0.9780267477035522},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8433464169502258},{"id":"https://openalex.org/C2780892749","wikidata":"https://www.wikidata.org/wiki/Q929518","display_name":"Expanded Disability Status Scale","level":3,"score":0.6625736951828003},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.614936113357544},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5265995264053345},{"id":"https://openalex.org/C2908698914","wikidata":"https://www.wikidata.org/wiki/Q2450337","display_name":"Interferon beta-1a","level":4,"score":0.412422239780426},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3681780695915222},{"id":"https://openalex.org/C2994247566","wikidata":"https://www.wikidata.org/wiki/Q2450337","display_name":"Interferon beta","level":3,"score":0.22783589363098145},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.18797245621681213},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.0},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.msard.2019.11.068","doi":"https://doi.org/10.1016/j.msard.2019.11.068","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.msard.2019.11.068","pdf_url":null,"source":{"id":"https://openalex.org/S2764622253","display_name":"Multiple Sclerosis and Related Disorders","issn_l":"2211-0348","issn":["2211-0348","2211-0356"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis and Related Disorders","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2903866675","https://openalex.org/W7220398354","https://openalex.org/W4389447588","https://openalex.org/W4389465430","https://openalex.org/W4411750559","https://openalex.org/W2889301354","https://openalex.org/W2989866631","https://openalex.org/W6886006237","https://openalex.org/W2904749964","https://openalex.org/W2954466446"],"abstract_inverted_index":null,"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-03-23T00:00:00"}